To Observe the Effect of Edaravone Combined with Cinepazide Maleate on Patients with Acute Cerebral Infarction Serum MMP-3, MMP-9, TIMP-1, EPCs
Ya-ru DONG,Xiu-yun XUE,Lin ZHANG,Li-li SHI,Xiao-yan DANG
DOI: https://doi.org/10.13241/j.cnki.pmb.2018.23.033
2018-01-01
Abstract:Objective: To study the effect of edaravone combined with cinepazide maleate on patients with acute cerebral infarction serum MMP-3, MMP-9, TIMP-1, EPCs. Methods: 114 cases with acute cerebral infarction were researched, according to the random number table they were divided into combined treatment group(n=57) and the single treatment group(n=57). The single treatment group was only treated with edaravone, and the combined treatment group was treated with edaravone and cinepazide malete. They were compared with clinical treatment effect, NIHSS score change, laboratory index level change, blood lipid level change and adverse reactions. Results: After treatment, combined treatment group cured and significantly improved patients reached 49 cases, the total effective rate was 85.96％, and the single treatment group cured and significant progress in patients with only 39 cases, the total effective rate was 68.42％, there was significant difference between two groups (P＜0.05). After the treatment of 14 d and 28 d, the scores of patients were significantly lower than those before treatment, while the level of decrease in the combined treatment group was better than that in the single treatment group (P＜0.05). Two groups of patients with MMP3 and MMP9 levels decreased significantly, while TIMP-1 and EPCs levels increased significantly, and the combined treatment group MMP3 and MMP9 decreased and TIMP-1 and EPCs levels were significantly better than the single treatment group (P＜0.05). After treatment of 14 d and 28 d, the indexes of blood lipid in patients decreased significantly compared with the previous measurement, and the decrease in the individual treatment group was more obvious than that in the combined treatment group (P＜0.05). The adverse reaction rate was 5.26％ in the combined treatment group, the adverse reaction rate in the single treatment group was 10.53％, and the adverse reaction rate was not statistically significant(P＞0.05). Conclusion: Edaravone combined with cinepazide maleate used in the treatment of patients with acute cerebral infarction is effective, effectively improve the serum levels of MMP-3, MMP-9, TIMP-1, EPCs and blood lipid abnormalities, promote angiogenesis, protect the brain tissue of patients.